"In the third quarter of 2021, license revenue rose 37 percent and support revenue rose 12 percent. Overall, net sales rose 15 percent and operating loss totaled
THIRD QUARTER (JULY-
- Order intake
SEK 127.9 M (138.5) -
Net sales
SEK 136.4 M (119.1) -
Operating loss
SEK -26.6 M (-29.5) -
Loss after tax
SEK -22.0 M (-26.2) -
Loss per share before/after dilution
SEK -0.64 (-0.76) -
Cash flow
SEK -10.1 M (pos: 21.7) -
Order backlog
SEK 1,211.6 M (1,228.5) at the end of the period
FIRST NINE MONTHS (JANUARY-
- Order intake
SEK 462.7 M (615.6) -
Net sales
SEK 453.1 M (491.8) -
Operating loss
SEK -36.8 M (profit: 11.1) -
Loss after tax
SEK -31.3 M (profit: 5.1) -
Loss per share before/after dilution
SEK -0.91 (earnings: 0.15) -
Cash flow
SEK -51.6 M (pos: 83.4)
SIGNIFICANT EVENTS DURING THE THIRD QUARTER
- The RayStation® treatment planning system was sold to more leading cancer centers, including National Cancer Centre Singapore (NCCS),
Centro de Tratamiento e Investigación sobre cáncerLuis Carlos Sarmiento Angulo (CTIC) inColombia , andQueen Elizabeth Hospital (QEH) inHong Kong . In addition, Iridium Network inBelgium expanded its existing RayStation installation. -
In September, Iridium Network in
Belgium , one ofRaySearch's development partners for RayCare, decided to invest in RayCare as its primary oncology information system. -
In September, RayStation was taken into clinical use together with
Accuray's CyberKnife therapy device at Centre hospitalier universitaire vaudois (CHUV) inSwitzerland .
THE COVID-19 PANDEMIC
- The COVID-19 pandemic with temporary reorganizations in healthcare also had a negative impact on sales in the third quarter.
RaySearch expects that the negative effects of the COVID-19 pandemic on the company's sales and earnings will continue for some months to come, mainly because orders may be delayed.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- In October, RayCare was taken into clinical use with
Accuray's Radixact® treatment delivery system atSwiss Medical Network inSwitzerland . RaySearch and IBA are expanding their collaboration around proton therapy in the areas of FLASH radiotherapy, proton arc therapy and the treatment of tumors in motion.RaySearch andMevion Medical Systems are expanding their collaboration on the development of treatment planning methods for FLASH radiotherapy with the Mevion S250i Proton Therapy System.-
When access is granted to the new head office premises in the fourth quarter of 2021, total assets are expected to increase approximately
SEK 466 M in accordance with IFRS 16. -
Torbjörn Wingårdh was appointed new CFO of
RaySearch as ofNovember 15, 2021 .
TELECONFERENCE IN CONJUNCTION WITH THE INTERIM REPORT
CEO Johan Löf and CFO
For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/5435207
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO Tel: +46 8 510 530 00 E-mail: johan.lof@raysearchlabs.com
The information contained in this interim report is such that
ABOUT
* Subject to regulatory clearance in some markets.
https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---september-30--2021,c3455925
https://mb.cision.com/Main/1102/3455925/1497941.pdf
(c) 2021 Cision. All rights reserved., source